This paper reviews the literature on reference pricing (RP)
in pharmaceutical markets. The RP strategy for cost containment
of expenditure on drugs is analyzed as part of the procurement
mechanism. We review the existing literature and the
state-of-the-art regarding RP by focusing on its economic
effects. In particular, we consider: (1) the institutional
context and problem-related factors which appear to underline
the need to implement an RP strategy; i.e., its nature,
characteristics and the sort of health care problems commonly
addressed; (2) how RP operates in practice; that is, how third
party-payers (the insurers/buyers) have established the RP
systems existing on the international scene (i.e., information
methods, monitoring procedures and legislative provisions); (3)
the range of effects resulting from particular RP strategies
(including effects on choice of appropriate pharmaceuticals,
insurer savings, total drug expenditures, prices of referenced
and non-referenced products and dynamic efficiency; (4) the
market failures which an RP policy is supposed to address and
the main advantages and drawbacks which emerge from an analysis
of its effects. Results suggest that RP systems achieve better
their postulated goals (1) if cost inflation in pharmaceuticals
is due to high prices rather than to the excess of prescription
rates, (2) when the larger is the existing difference in prices
among equivalent drugs, and (3) more important is the actual
market for generics.
Other authors
Universitat Pompeu Fabra. Departament d'Economia i Empresa